Returning guest, Dr. Bruce Dorr, MD, Senior Medical Advisor at Biote discusses a patient case study published in the peer-reviewed medical journal “The Aging Male” detailing how a 54-year-old male patient with a spontaneous fracture and osteoporosis achieved a complete recovery of osteoporosis after one year of pelleted testosterone therapy.
INTERVIEWS
My Type 2 Diabetes and Me: How I Learned to Manage My Blood Sugar Through Healthy Eating, Exercise and Treatment
Maria, who runs her own salon business in Pennsylvania and lives with type 2 diabetes, shares her personal journey with diagnosis, adopting a new lifestyle, and her experience with Ozempic ® (semaglutide) injection. She is joined by Dr. Juan Frias, Medical Director of Velocity Clinical Research, Los Angeles who discusses the relationship between food, exercise, and type 2 diabetes, the importance of having a diabetes management plan, and information about the safety and potential side effects of Ozempic ®.
Working While Pregnant – New Pregnant Workers Fairness Act
Charlotte Burrows, Chair for the U.S. Equal Employment Opportunity Commission discusses the new Pregnant Workers Fairness Act (PWFA) and who it protects. She provides a few examples of reasonable accommodations and what other federal laws may apply to pregnant workers and new parents.
Biotricity – AI in the Future of Wearable Heart Monitoring Devices
Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity, Inc., a med tech company, discusses the role of AI in the future of wearable heart monitoring devices and the FDA-cleared “Bioflux,” Biotricity’s latest technology being used by cardiologists nationwide to remotely monitor their patient’s heart conditions.Early intervention not only can reduce hospital stays but save money and save lives.
Survey Found More than 3/4 People Used Addictive Behavior as Coping Mechanism
Dawn Johnson, a psychiatric nurse practitioner at the Indiana Center For Recovery discusses a survey that found that 94% of people agree that substance and behavioral addictions mask underlying mental health issues and other findings. She also talks about medication failure and how the GeneSight test allows medical providers to swab the inside of their patient’s cheek to give providers information about a patient’s genetics. The test’s results report shows which medications may require dose adjustment, may be less likely to work, or may have an increased risk of side effects based on the patient’s DNA.
Positive XARELTO(R) Sleep Apnea Data
Craig Coleman, PharmD, FASHP, FACC, Professor at the University of Connecticut discusses new data supporting XARELTO ® (rivaroxaban) efficacy and safety compared to warfarin in patients with nonvalvular atrial fibrillation (NVAF) and concomitant obstructive sleep apnea (OSA) which was published in “TH Open”, a peer-reviewed vascular biology and medicine journal.
Aptevo Therapeutics – Focus on Novel Immuno-Oncology Therapeutics
Dr. Dirk Huebner, MD, Chief Medical Officer at Aptevo Therapeutics, a biotech company, discusses the company’s focus on bringing novel immuno-oncology therapeutics to market. They leverage the innovative ADAPTIR™ and ADAPTIR-FLEX™ platform technologies to create therapeutic candidates designed to improve outcomes for cancer patients.
Mental Health Awareness – Support for Caregivers of Schizophrenia Patients
Psychiatrist, Dr. Rakesh Amin, MD, discusses the toll that schizophrenia takes on caregivers, how caregivers of schizophrenia patients can best support themselves, as well as their patients, and how caregivers can help patients establish a successful treatment plan. Dr. Amin talks about newer treatment options, such as long-acting injectables, that can help improve patient adherence, reduce stress, and allow freedom from taking a pill every day.
BioLife Plasma Services
Hema Tallman, SVP and Global Head of BioLife Plasma Services at Takeda, an industry leader in the collection of high-quality plasma and a supporting driver in the production of life-saving plasma-derived therapies (PDTs). She discusses the importance of the consumer experience by leveraging her experience in health retail as she drives BioLife’s efforts to create a future-ready organization that can meet the growing needs of patients who rely on PDTs. Tallman also shares her personal insights that supported her growth as a leader.
Halia Therapeutics – Eliminating Chronic Inflammation by Targeting the NLRP3 Inflammasome
Dr. David Bearss, PhD, President and CEO at Halia Therapeutics, a clinical-stage biopharma company developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases discusses the company’s lead compound, HT-6184, which prevents the formation of the NLRP3 inflammasome complex and subsequently inhibits the production and release of pro-inflammatory cytokines to ultimately shut down chronic inflammation. Halia is currently conducting a Phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of HT-6184 in healthy human participants.